Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.

MLA

Brüggemann, C., et al. “Predictive Value of PD-L1 Based on MRNA Level in the Treatment of Stage IV Melanoma with Ipilimumab.” Journal of Cancer Research and Clinical Oncology, vol. 143, no. 10, Oct. 2017, pp. 1977–84. EBSCOhost, https://doi.org/10.1007/s00432-017-2450-2.

APA

Brüggemann, C., Kirchberger, M. C., Goldinger, S. M., Weide, B., Konrad, A., Erdmann, M., Schadendorf, D., Croner, R. S., Krähenbühl, L., Kähler, K. C., Hafner, C., Leisgang, W., Kiesewetter, F., Dummer, R., Schuler, G., Stürzl, M., & Heinzerling, L. (2017). Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. Journal of Cancer Research and Clinical Oncology, 143(10), 1977–1984. https://doi.org/10.1007/s00432-017-2450-2

Chicago

Brüggemann, C, M C Kirchberger, S M Goldinger, B Weide, A Konrad, M Erdmann, D Schadendorf, et al. 2017. “Predictive Value of PD-L1 Based on MRNA Level in the Treatment of Stage IV Melanoma with Ipilimumab.” Journal of Cancer Research and Clinical Oncology 143 (10): 1977–84. doi:10.1007/s00432-017-2450-2.